在炎症性肠病中过渡到皮下Infliximab与Vedolizumab:一个前性的多中心研究
Mariabeatrice Principi1, Irene Vita Brescia2, Elisa Stasi3
1Gastroenterology Unit, DiMePreJ, "Aldo Moro" University, Bari, Italy. b.principi@gmail.com.
Digestive diseases and sciences
|September 30, 2024
概括
将炎症性肠病患者从静脉注射转换为皮下注射的Infliximab或Vedolizumab是安全的,并改善了生活质量,特别是在前六个月. 长期生活质量在12个月后出现下降.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉 (IV) 到皮下 (SC) 给药是炎症性肠病 (IBD) 治疗的新兴选择,如Infliximab (IFX) 和Vedolizumab (VDZ).
- 患者的坚持,治疗持续性和生活质量 (QoL) 是评估治疗方式的关键因素.
研究的目的:
- 为了在IBD患者中比较SC IFX和SC VDZ之间的坚持性,治疗持久性和QoL.
- 评估患者报告的结果和SC管理的安全概况.
主要方法:
- 一项前性,观察性,多中心研究,涉及108名IBD患者从IV切换到SC IFX或VDZ.
- 使用简短IBD问卷 (sIBDQ) 测量了QOL;一个6项调查评估了担忧和期望.
- 系统地记录了不良事件,安全性,担忧和满意度.
主要成果:
- 大多数患者接受了SC路线,SCIFX和SCVDZ组之间的治疗持久性相似.
- 转换后6个月QOL显著改善 (p=0.004),但在两组中下降了12个月.
- SC给药耐受性很好,局部反应相似;IFX组报告了更多的系统反应 (11.6% vs 7.14%) 没有住院治疗.
结论:
- 从IV向SC的IFX或VDZ的过渡是IBD管理的安全和适当的选择.
- 患者的偏好和选择是成功治疗过渡的关键因素.
- SC 管理提供了显著的 QoL 益处,特别是在治疗的最初 6 个月内.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease II: Crohn's Disease
194
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
194
Drugs for Treatment of Ulcerative Colitis in IBD
128
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
128


